Skip to main content

Table 2 Central pathology review of all tissue cores contributing to the Test- and Validation-TMA series

From: The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation

 

Sites

CHUM

CHUdeQ-UL

MUHC

UHN

VPC

EXPECTED BENIGN CORES

623

545

627

773

691

Reviewed as Benign

597

436

485

673

511

Reviewed as Cancer

0

19

67

25

88

Reviewed as Uninformativea

26

90

75

75

92

EXPECTED TUMOR CORES

954

1269

953

1042

1135

Reviewed as Cancer

845

944

707

825

825

Reviewed as Benign

52

133

109

109

192

Reviewed as Uninformativea

57

192

137

108

118

  1. aProstatic intraepithelial neoplasia, intraductal carcinoma, atypical small acinar proliferation, < 5% tumor cells, stroma only, muscle or inflammation